This page shows the latest faldaprevir news and features for those working in and with pharma, biotech and healthcare.
And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C. ... Boehringer drops faldaprevir. Meanwhile Boehringer confirmed it has withdrawn the application for its hepatitis C treatment faldaprevir following a review of its
After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldaprevir - a protease inhibitor - because the "HCV treatment environment has significantly and ... Faldaprevir was always likely to be at
Boehringer's marketing application is largely based on the results of the STARTverso studies, which compared faldaprevir or placebo on top of interferon and ribavirin therapy. ... Meanwhile, faldaprevir is also in pivotal trials as part of an
Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral
That is significant because some patients with hepatitis C virus also have HIV, and as a result Boehringer has included co-infected patients in its faldaprevir trials programme. ... Boehringer recently started pivotal trials of an interferon-free
The launch of the US-focused HepCRedefined.com site came on the day the pharma company moved its interferon-free hep C regimen, which combines faldaprevir and BI 207127, into phase
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...